Document is current
Any future updates will be listed below
-
Authors
Lobel, Caryn J. https://orcid.org/0000-0003-2552-5981
Laney, Dawn A.
Yang, Jingjing
Jacob, David
Rickheim, Amy
Ogg, Carol Z.
Clynes, Diana
Dronen, Jessica
-
Funding
Funding for this research was provided by:
National Institutes of Health (NIH/NIGMS R35GM138313)
Chiesi USA
Sanofi
Amicus Therapeutics
- License Information
-
More Information
Article History
Received: 26 October 2023
Accepted: 20 December 2023
First Online: 4 January 2024
Declarations
:
: This study received approval from the Emory University Institutional Review Board (IRB no. 00003599). Approval for consent was waived.
: Not applicable.
: C. J. L. declares no competing interests. D. A. L., consults with Chiesi, Spark Therapeutics, Sanofi-Genzyme, Takeda, Protalix, and Amicus Therapeutics and Founder of ThinkGenetic, Inc. J. Y. declares no competing interests. D. J., CEO of ThinkGenetic, Inc.; director of ThinkGenetic Foundation, Inc., and stock options from ThinkGenetic, Inc. A. R., employee of ThinkGenetic Foundation, Inc. C. Z. O., volunteer advisor to ThinkGenetic, Inc.; received a monthly consulting fee between April 2020 and April 2021 from the Takeda Pharmaceuticals Medical Communications; received a stock grant in 2017 from ThinkGenetic, Inc. D. C.; and executive director of the American Association of Kidney Patients. J. D., owns stock options as an employee of ThinkGenetic, Inc.; board member of ThinkGenetic Foundation, Inc.; chair of the Sanofi Genzyme North American Fabry Registry Board; and stock options ThinkGenetic, Inc.
